Design Therapeutics (DSGN) Projected to Release Earnings on Wednesday

Design Therapeutics (NASDAQ:DSGN) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.38) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:30 AM ET.

Design Therapeutics (NASDAQ:DSGN) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.02. On average, analysts expect Design Therapeutics to post ($1.41) EPS for the current fiscal year and ($1.63) EPS for the next fiscal year.

Design Therapeutics Trading Up 2.8%

NASDAQ:DSGN opened at $10.63 on Wednesday. Design Therapeutics has a 1 year low of $6.16 and a 1 year high of $17.25. The firm has a 50 day moving average of $12.93 and a 200-day moving average of $12.10. The stock has a market capitalization of $665.25 million, a P/E ratio of -9.01 and a beta of 1.68.

Analyst Ratings Changes

A number of research firms have commented on DSGN. Wells Fargo & Company began coverage on Design Therapeutics in a research note on Friday, October 2nd. They issued an “overweight” rating and a $26.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Design Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Design Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $17.86.

About Design Therapeutics

Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.

The company’s research has focused on disorders affecting the nervous system, muscles and eyes.